5,039
+3.73%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eisai Co
Its shares trade on Tokyo Stock Exchange under the ticker 4523.T. It has been listed since 14 September 1961. In the fiscal year to 31 March 2026, it reported revenue of ¥825.38bn and net income of ¥38.56bn. At that date it held total assets of ¥1.45trn and shareholders' equity of ¥898.99bn.
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. The company is headquartered in Bunkyo-Ku, Tokyo-To. The firm operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The firm is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Sept 1961
- Employees
- 10,998
- Website
- eisai.co.jp ↗
Leadership
Pay as last reported
- Mr. Fumihiko IkeChairman of the Board of Directors, Independent Director
- Mr. Haruo NaitoChief Executive Officer, Representative Executive Officer, Director, since 1983¥211.0m
- Mr. Mitsuru ShomonExecutive Officer, Chief Financial Officer
- Mr. Keisuke NaitoRepresentative Senior Managing Executive Officer, Chief Operating Officer, Chief Growth Officer
- Mr. Teruyuki MasakaExecutive Officer, Chief Human Resource Officer
- Mr. Makoto HoketsuExecutive Officer, Chief Information Officer
- Mr. Shin KatoExecutive Officer, Chief Compliance Officer, Director of Legal Affairs
- Mr. Terushige IikeSenior Managing Executive Officer, Chief Strategy & Planning Officer
- Mr. Masatomi AkanaManaging Executive Officer, Chief Government Relations Officer, Chief IR Officer
- Ms. Yanhui FengManaging Executive Officer, President of Subsidiary
- Mr. Gary HendlerManaging Executive Officer, President of EMEA Region, Chairman & Chief Executive Officer of Subsidiary
- Mr. Takashi OwaManaging Executive Officer, Chief Scientific Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 93
- Environment
- 99
- Social
- 99
- Governance
- 81
- Direct emissions (scope 1)
- 48,586 t
- Energy emissions (scope 2)
- 2,673 t
- Value chain emissions (scope 3)
- 563,928 t
- Women in the workforce
- 43%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Eisai Co Ltd has a strong global presence and is a leading player in the pharmaceutical industry. They have a diverse portfolio of products and a strong brand reputation. The company has a dedicated research and development team and invests significantly in innovation. They have a robust manufacturing and supply chain network which ensures timely delivery of their products.
- Eisai Co Ltd has established strategic partnerships and collaborations with other pharmaceutical companies, enabling them to access new markets and expand their product offerings. They have a strong financial position and a history of consistent revenue growth.
Weaknesses
- One of the weaknesses of Eisai Co Ltd is their heavy reliance on a few key products for a significant portion of their revenue. This leaves them vulnerable to market fluctuations and competition. They have a relatively small market share in certain regions, limiting their potential for growth.
- The company has faced challenges in ensuring regulatory compliance, which can result in delays in product approvals and launches. They also face risks associated with patent expirations and generic competition.
Opportunities
- Eisai Co Ltd has the opportunity to expand their presence in emerging markets where there is a growing demand for healthcare products. They can also explore new therapeutic areas and invest in research and development to develop innovative treatments.
- The aging population in many countries presents an opportunity for Eisai Co Ltd to develop and market products catering to the specific needs of older adults. They can also focus on developing personalized medicine and digital healthcare solutions.
Threats
- Eisai Co Ltd faces intense competition from other pharmaceutical companies, including both established players and emerging biotech firms. The ever-changing regulatory environment and increasing scrutiny on pricing and reimbursement pose challenges to their business.
- The company is also exposed to risks associated with potential adverse effects of their products, which could lead to lawsuits and reputational damage. Changes in healthcare policies and the potential impact of global economic uncertainties are additional threats they need to consider.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.